Tilray® Imports Bulk Supply of Medical Cannabis Oil into the United Kingdom
NANAIMO, B.C. – Tilray Inc. (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced it has imported medical cannabis oral solutions in bulk into the United Kingdom from its Good Manufacturing Practices (GMP)-certified facility in Canada. This export allows Tilray to provide authorized U.K. patients in need with a locally maintained supply of medical cannabis oral solutions.
In September 2018, Tilray announced the successful import of Tilray 2:100 medical cannabis oil for a pediatric patient in need in the United Kingdom. Tilray’s 2:100 cannabis oil was supplied via a government-approved special access program following the U.K. Home Secretary’s historic announcement that declared prescriptions of cannabis-derived medicines legal for patients with an exceptional clinical need.
“As demand ramps up in the U.K., Tilray is well positioned to be a leading supplier of medical cannabis products,” says Sascha Mielcarek, Managing Director of Tilray Europe. “Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients’ quality of life. We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the U.K. and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”
Tilray has six medical cannabis products approved for medical use in the U.K. that can be made available to patients with medical cannabis prescriptions obtained through private practice or the National Health Service. Tilray anticipates supplying a variety of cannabidiol (CBD)-dominant, tetrahydrocannabinol (THC)-dominant and balanced oral solutions for patients looking to use medicines derived from cannabis.
“This bulk import of Tilray medical cannabis oral solutions provides patients in need access to a sustained supply of GMP-certified, high quality medical cannabis,” says Catherine Jacobson, Tilray’s Vice President of Medical and Regulatory Affairs. “This is an important step in improving access in the U.K. Tilray will continue to advocate for reasonable patient access to medical cannabis in the U.K. and countries around the world.”
The Murdoch Children’s Research Institute led pilot study to evaluate the feasibility, acceptability and efficacy of cannabidiol (CBD) oral solution in reducing Severe Behavioral Problems in children with Intellectual Disabilities
Tilray CBD and THC capsules will be used in a study examining the safety, tolerability and effectiveness of medical cannabis on immune activation in people living with HIV being conducted by the McGill University Health Centre
Former Goldman Sachs Managing Director Andrew Pucher joins Tilray to lead the company’s global corporate development activity, including M&A and corporate investments
NANAIMO, B.C. - Today, Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announces the expansion of its global senior leadership team with the appointment of Andrew Pucher as Chief Corporate Development Officer. In his new role, Andrew will lead Tilray’s corporate development function, including the team that is responsible for M&A and corporate investments. He will be based in Toronto, ON, and report to CEO Brendan Kennedy.
Andrew joins Tilray from Goldman Sachs, where he was a Managing Director and most recently served as Head of Canadian Diversified Investment Banking, which included coverage of the Canadian cannabis industry. Previously, he was a member of Goldman Sachs’ Global Healthcare Investment Banking Group in New York, where he advised on more than $200 billion in announced M&A and financing transactions, with a focus on the biopharmaceutical sector. Andrew is a graduate of Simon Fraser University and earned a JD/MBA from York University.
Brendan Kennedy, Tilray’s CEO, said, “We’re pleased to welcome Andrew to our senior leadership team to execute strategic transactions that will further accelerate Tilray’s long-term global growth. Andrew shares our commitment to a disciplined, strategic approach in pursuing inorganic growth opportunities. His transaction experience and industry knowledge will be valuable as we work to capitalize on the many strategic opportunities available to us and continue to pursue the disruptive potential of cannabis across industries including pharmaceuticals, alcohol, consumer goods, functional food and beverage, retail and nutraceuticals.”
Recent Tilray transactions and partnerships include: forming a global partnership with Sandoz, a division of Novartis, to distribute its medical products; establishing a 50/50 joint venture with AB InBev, the world’s largest brewer, to develop THC and CBD beverages; signing an agreement to produce THC and CBD products for Authentic Brands Group portfolio of brands, which includes Muhammed Ali, Nine West, Spyder ski gear, Prince tennis wear, Marilyn Monroe, Juicy Couture and Elvis Presley; acquiring Natura Naturals Holdings, thereby increasing its cannabis supply; and most recently, announcing the acquisition of Manitoba Harvest, the world’s largest hemp company, accelerating the company’s entry into the natural foods space with hemp and CBD-infused food and wellness products for North America.
Over the past several months, Tilray has announced appointments to its senior leadership team, with executives from world-leading brands: Sascha Mielcarek joined Tilray from Grünenthal to become Managing Director, Europe; Greg Christopher joined from Nestle to become Tilray’s EVP of Operations; Rita Seguin came on board from Diageo to be Tilray’s EVP of Human Resources; Dara Redler, Tilray’s General Counsel worked previously at The Coca-Cola Company; and Charlie Cain as VP of Retail came from Starbucks Corporation.